Floatz logo

Therapeutic Allogeneic Lymphocytes

Relapsing Chronic Myelogenous Leukemia

University of ChicagoCell therapyPhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Relapsing Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Benadryl
City of Hope Medical Center
Phase 2BBB
Cediranib
M.D. Anderson Cancer Center
Phase 2BB
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Vorinostat
OHSU Knight Cancer Institute
Phase 2B

View all 17 →

Same molecule, other indications

Therapeutic Allogeneic Lymphocytes is also rated in:

chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →